Wikipedia -WSS

Wikipedia

author：fashion 2025-09-06 03:30:46 - browse：4

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Hospitals owned by private equity see complications spike 25%

WSS

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Eye stem cell transplant could help restore vision in injured people

Congress must give Medicare recipients genetic counseling access

ActiGraph execs on goal of drug approvals with digital endpoints

Drinking less cuts risk of oral cavity, esophageal cancer: Report

entertainment

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Bristol Myers buys into radiopharmaceuticals with RayzeBio

The high cost of giving birth even with insurance

Congress must give Medicare recipients genetic counseling access

Medicare proposal to cover medical devices draws a mixed reaction

Evacuations in place as 3 wildfires burn in eastern Washington state

Drug repurposing or repositioning? The language matters

Can sheer will power keep patients alive in their dying hours?

23andMe had bad news about my health. I wish a person had delivered it

Virtual care provider acquires bankrupt Pear's prescription apps

leisure time

Listen: Racing for gene therapy & a pioneering approval

In Spain, a hospital brews its own CAR

Cancer drug shortages' outsize impact on ovarian cancer patients

Patient advocates sound warning on FDA proposal on salt intake

David Ricks of Eli Lilly: best biopharma CEO of 2023

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

entertainment

focus

focus

leisure time